Actively Recruiting
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Led by Henry Ford Health System · Updated on 2026-02-03
268
Participants Needed
1
Research Sites
209 weeks
Total Duration
On this page
Sponsors
H
Henry Ford Health System
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this trial is to see if providing patients with alcohol-related liver disease with tailored alcohol use treatment options will increase engagement with treatment and correct possible misconceptions.
CONDITIONS
Official Title
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
-
Willingness to comply with all study procedures and availability for the duration of the study
-
Willing and able to provide informed consent
-
Enrolled at University of Michigan (UM) hepatology clinics or inpatients at UM Hospitals
-
Documented diagnosis of alcohol-related liver disease (ALD) (per protocol)
-
Recent alcohol use of any amount within the past 6 months as assessed by either patient interview, medical chart review, or positive alcohol biomarker (e.g. blood alcohol level, urinary ethyl glucuronide, urinary ethyl sulfate, or phosphatidylethanol) in the medical record.
-
No alcohol use treatment within the past 1 month including, but not limited to:
- Any professionally lead therapy with a mental health counselor (such as, one-on-one therapy, group therapy, couples or family therapy) with a primary aim of alcohol abstinence or reduction in alcohol use.
- Community-based alcohol recovery groups (such as, Alcoholics Anonymous, SMART Recovery, Celebrate Recovery, Refuge Recovery)
- Community-based church support groups primarily focused on alcohol abstinence or reduction in use.
- Residential (inpatient) alcohol treatment
- Intensive outpatient programs
- Any telehealth version of the above options
-
Access to a Smartphone or computer for purposes of follow-up. Those who do not have a Smartphone will be provided one along with a calling/data plan at no cost to subject by the study team for the duration of the research stud.
-
Ability to speak and comprehend English
You will not qualify if you...
- Unable to provide voluntary informed consent for any reason
- Substantially cognitively impaired as evidenced by Westhaven grade 2 or higher hepatic encephalopathy or a score >=10 on the Short Blessed Test for cognitive impairment.
- Unable to read or understand English
- Undergoing active evaluation for liver transplantation, is listed for liver transplant, or is post-transplantation
- Is enrolled in the multidisciplinary ALD clinic at Michigan Medicine
- Any other medical condition or circumstance that precludes safe and meaningful participation in the study
- History of nonadherence to previous clinical or research studies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry Ford Health
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
M
Matthew Melican
CONTACT
J
Jessica Mellinger, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here